Toward a new era of trust and transparency in clinical trials

JAMA - Journal of the American Medical Association

Volumn 316, Issue 13, 2016, Pages 1353-1354

  Hudson, Kathy L ^a   Lauer, Michael S ^a   Collins, Francis S ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

CLINICAL COMPETENCE; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; HUMAN; NATIONAL HEALTH ORGANIZATION; ORGANIZATION AND MANAGEMENT; PROGRAM DEVELOPMENT; QUALITY CONTROL; STANDARDS; TOTAL QUALITY MANAGEMENT; TRUST; UNITED STATES;

CLINICAL COMPETENCE; CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); PROGRAM DEVELOPMENT; QUALITY CONTROL; RESEARCH SUPPORT AS TOPIC; TOTAL QUALITY MANAGEMENT; TRUST; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84995810464     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.14668     Document Type: Note

References (11)

1. Institute of Medicine Forum on Drug Discovery, Development, and Translation. Transforming Clinical Research in the United States: Challenges and Opportunities:Workshop Summary.Washington, DC: National Academies Press; 2010.
2. Kramer JM, Smith PB, Califf RM. Impediments to clinical research in the United States. Clin Pharmacol Ther. 2012;91(3):535-541.
3. Hudson KL, Collins FS. Sharing and reporting the results of clinical trials. JAMA. 2015;313(4):355-356.
4. Chen R, Desai NR, Ross JS, et al. Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers. BMJ. 2016;352:i637.
5. National Institutes of Health. NIH and FDA Request for Public Comment on Draft Clinical Trial Protocol Template for Phase 2 and 3 IND/IDE Studies. http://grants.nih.gov/grants/guide/notice-files/NOT-OD-16-043.html. Accessed September 7, 2016.
6. Wagner TH, Murray C, Goldberg J, Adler JM, Abrams J. Costs and benefits of the national cancer institute central institutional review board. J Clin Oncol. 2010;28(4):662-666.
7. National Institutes of Health. Final NIH Policy on the Use of a Single Institutional Review Board for Multi-Site Research. https://grants.nih.gov/grants/guide/notice-files/NOT-OD-16-094.html. Accessed September 7, 2016.
8. National Center for Advancing Translational Sciences, National Institutes of Health. NCATS SMART IRB Reliance Authorization Agreement. https://ncats.nih.gov/files/smart-authorization-agreement-6-2016.pdf. Accessed September 7, 2016.
9. National Institutes of Health. NIH Policy on dissemination of NIH-funded clinical trial information. Fed Regist. 2016;81(183). https://www.federalregister.gov/.
10. Zarin DA, Tse T, Williams RJ, Carr S. Trial reporting in ClinicalTrials.gov-the final rule. N Engl J Med. doi:10.1056/NEJMsr1611785
11. Department of Health and Human Services. Final Rule-Clinical Trials Registration and Results Information Submission.Washington, DC. Fed Regist. 2016;81(183). https://s3.amazonaws.com/public-inspection.federalregister.gov/2016-22129.pdf.